Abstract:Patients with COVID-19 present a wide spectrum of disease severity, from asymptomatic cases in the majority to serious disease leading to critical care and even death. Clinically, four different scenarios occur within the typical disease timeline: first, an incubation and asymptomatic period; second, a stage with mild symptoms due mainly to the virus itself; third, in up to 20% of the patients, a stage with severe symptoms where a hyperinflammatory response with a cytokine storm driven by host immunity induces acute respiratory distress syndrome; and finally, a post-acute sequelae (PASC) phase, which present symptoms that can range from mild or annoying to actually quite incapacitating. Although the most common manifestation is acute respiratory failure of the lungs, other organs are also frequently involved. The clinical manifestations of the COVID-19 infection support a key role for endothelial dysfunction in the pathobiology of this condition. The virus enters into the organism via its interaction with angiotensin-converting enzyme 2-receptor that is present prominently in the alveoli, but also in endothelial cells, which can be directly infected by the virus. Cytokine release syndrome can also drive endothelial damage independently. Consequently, a distinctive feature of SARS-CoV-2 infection is vascular harm, with severe endothelial injury, widespread thrombosis, microangiopathy, and neo-angiogenesis in response to endothelial damage. Therefore, endothelial dysfunction seems to be the pathophysiological substrate for severe COVID-19 complications. Biomarkers of endothelial injury could constitute strong indicators of disease progression and severity. In addition, the endothelium could represent a very attractive target to both prevent and treat these complications. To establish an adequate therapy, the underlying pathophysiology and corresponding clinical stage should be clearly identified. In this review, the clinical features of COVID-19, the central role of the endothelium in COVID-19 and in other pathologies, and the potential of specific therapies aimed at protecting the endothelium in COVID-19 patients are addressed.

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

Endothelial Dysfunction and SARS-CoV-2 Infection: Association and Therapeutic Strategies

Viral Endothelial Dysfunction: A Unifying Mechanism for COVID-19

The Mechanism of Multiple Organ Dysfunction Syndrome in Patients with COVID‐19

The mechanism of multiple organ dysfunction syndrome in patients with COVID-19

Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications

Endothelial cells and SARS-CoV-2: An intimate relationship

Pulmonary Endothelial Dysfunction and Thrombotic Complications in Patients with COVID-19

Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?

SARS-CoV-2 induced vascular endothelial dysfunction: direct or indirect effects?

Understanding the Impact of SARS-CoV-2 on Lung Endothelial Cells: Brief Mechanisms Unveiled

Endothelial cell infection and dysfunction, immune activation in severe COVID-19

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

Endothelial Dysfunction and Thrombosis in Patients With COVID-19—Brief Report

SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro

The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment

Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence

COVID-19 is, in the end, an endothelial disease

COVID-19 and Microvascular Disease: Pathophysiology of SARS-CoV-2 Infection With Focus on the Renin-Angiotensin System

Vascular Manifestations of COVID-19 – Thromboembolism and Microvascular Dysfunction